Isoprenoids as mediators of the biological effects of statins

[1] Aikawa M, 2001, CIRCULATION, V103, P276

[2] LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE [J]. CIRCULATION, 1993, 87 (06) : 1781 - 1791

[3] Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women [J]. LANCET, 2000, 355 (9222) : 2185 - 2188

[4] Collins R, 2002, INT J CLIN PRACT, V56, P53

[5] New insights into the pharmacodynamic and pharmacokinetic properties of statins [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) : 413 - 428

[6] Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization [J]. CIRCULATION, 2001, 103 (07) : 926 - 933

[7] HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data [J]. ATHEROSCLEROSIS, 1998, 138 (01) : 11 - 24

[8] Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines:: an in vitro study [J]. CARCINOGENESIS, 2001, 22 (08) : 1139 - 1148

[9] HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (03) : 391 - 397

[10] Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) : 8880 - 8885

[1] Aikawa M, 2001, CIRCULATION, V103, P276

[2] LIPID-LOWERING AND PLAQUE REGRESSION - NEW INSIGHTS INTO PREVENTION OF PLAQUE DISRUPTION AND CLINICAL EVENTS IN CORONARY-DISEASE [J]. CIRCULATION, 1993, 87 (06) : 1781 - 1791

[3] Inhibitors of hydroxymethylglutaryl-coenzyme A reductase and risk of fracture among older women [J]. LANCET, 2000, 355 (9222) : 2185 - 2188

[4] Collins R, 2002, INT J CLIN PRACT, V56, P53

[5] New insights into the pharmacodynamic and pharmacokinetic properties of statins [J]. PHARMACOLOGY & THERAPEUTICS, 1999, 84 (03) : 413 - 428

[6] Pravastatin treatment increases collagen content and decreases lipid content, inflammation, metalloproteinases, and cell death in human carotid plaques - Implications for plaque stabilization [J]. CIRCULATION, 2001, 103 (07) : 926 - 933

[7] HMG-CoA reductase inhibitor therapy and stroke risk reduction: an analysis of clinical trials data [J]. ATHEROSCLEROSIS, 1998, 138 (01) : 11 - 24

[8] Cerivastatin, an inhibitor of HMG-CoA reductase, inhibits the signaling pathways involved in the invasiveness and metastatic properties of highly invasive breast cancer cell lines:: an in vitro study [J]. CARCINOGENESIS, 2001, 22 (08) : 1139 - 1148

[9] HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway [J]. JOURNAL OF CLINICAL INVESTIGATION, 2001, 108 (03) : 391 - 397

[10] Stroke protection by 3-hydroxy-3-methylglutaryl (HMG)-CoA reductase inhibitors mediated by endothelial nitric oxide synthase [J]. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1998, 95 (15) : 8880 - 8885